MARKETS
Earnings

Unicycive Therapeutics Q2 EPS $(0.06) Beats $(0.34) Estimate

Aug 12, 2026 · 06:43 AM ET· updated 2h ago

Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.34) by 82.35 percent. This is a 88.46 percent increase over losses of $(0.52) per

Share
Why It Matters

Unicycive lost less money than experts predicted, which is good news. When a company loses money slower than expected, it shows they're getting better at controlling costs.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.